Metastasis remains an important clinical problem. In gastrointestinal cancers it is the single most important determinant of death. The incidence of metastatic disease from colorectal cancer at presentation is 25%.' Even after curative surgical resection the five year survival rate is no more than 50% with an overall five year survival rate for colorectal cancer of 25-30%.2 3 The presence of liver metastases confers a median survival of only six months,4 figures that have essentially remained unchanged for over 40 years. At present our armamentarium against colorectal metastasis is weak. Surgery is limited to a fraction of cases and the alternative is systemic or regional chemotherapy. Results from such treatments are poor, only about 15-20% of tumours responding to systemic chemotherapy with marginal benefits in terms of survival.5 Such dismal figures lead to the conclusion that perhaps novel approaches are required in the prevention, early diagnosis, and treatment of liver metastasis. The questions that therefore arise are does modern science have anything to offer towards this problem and where is current research leading from a clinical perspective. A detailed description of the metastatic process is beyond the scope of this article. The role of oncogenes and tumour suppressor genes in the neoplastic process has been previously described and will not be referred to either. Here, we highlight two areas of current research in cell biology, namely, adhesion molecules and a group of matrix degrading enzymes, the metalloproteinases, and their roles in the progression and metastasis of tumours.
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The understanding of tumour cell biology is a prerequisite for the development of new prognostic and therapeutic tools. Current theories embrace notions of imbalances and deregulation of host derived and tumour derived factors, which result in uncontrolled proliferation, invasion, and metastasis.6 The process of metastasis, however, is not random. It consists of a series of linked, sequential steps that must be completed if a metastasis is to develop.7 Tumour cells need to attach to host cellular and extracellular matrix determinants; this has to be followed by the enzymatic degradation of barriers such as the basement membrane to permit extravasation into the blood or lymphatic system. Locomotion within the system to the target organ followed by reattachment and the induction of independent growth of these tumour cells are further steps in the development of a metastasis.6 8 Moreover, it is now well recognised that tumours contain multiple cell populations exhibiting a wide range of biological heterogeneity in several parameters including their ability to invade and metastasise.9 As the vascular system is generally a hostile environment to tumour cells, metastases must arise from a cell subpopulation that is selected in terms of survival. Studies have shown that 24 hours after the intravenous inoculum of radiolabelled tumour cells, less than 0 1/% survive to proliferate into metastases.'0 The size of this subpopulation varies with time and between tumours. This biological variation represents a major obstacle to effective treatment. poration of metalloproteinase inhibition on to the therapeutic menu. The gradual accrual of knowledge of the cellular properties of tumours that determine the metastatic phenotype and the impact of molecular biology techniques entailed in their unravelling promises much for the future. Predictors of tumour behaviour may well facilitate the recognition of tumours that are likely to metastasise and permit us a window in which treatment could be instituted. These same markers could form the basis of such treatment. Modulation of cellular function through genetic approaches or peptide treatments that block steps in the metastatic cascade can now be evaluated in animal models. The transition of such approaches from the laboratory to the clinical setting may not be far away. 63 The concept of neoplastic dissemination being the ultimate expression of cellular anarchy is now no longer tenable. Metastasis is a regimented selective process whose control at the molecular level is hierarchial. The exploitation of this knowledge may provide the next real step forward in the creation of novel therapeutic strategies.
Adhesion molecules
noted with the integrins and has been confirmed in several independent studies. There is indirect evidence to suggest that E-cadherin loss in vivo is possibly a later event in the genesis of these tumours when compared with integrin down regulation.22 This is of particular interest as another cell-cell adhesion molecule, namely N-CAM, a member of the immunoglobulin superfamily, has been shown to have large degrees of sequence homology with the DCC (deleted in colorectal cancer) gene product in colorectal cancer. This recessive gene is lost in about 70% of colorectal cancers and is also thought to be a late occurrence in the progression of colorectal cancer.35 Further experimental studies have shown that blocking the function of E-cadherin by monoclonal antibodies renders cell lines invasive. Gene transfection experiments have clearly shown the importance of E
